Sartorius and GE Agree on Cross-Licensing

Sartorius Stedim Biotech and GE Healthcare Life Sciences have drawn up a patent cross-licensing agreement enabling further development of each company’s current and future biopharmaceutical manufacturing technologies.

“Signing this agreement represents our mutual respect for intellectual property. In the immediate term it will enable us to employ the technologies covered by the patents in the license agreements to further advance the controls of single use devices,”

said Catarina Flyborg, General Manager BioProcess Products at GE Healthcare Life Sciences. “Furthermore our customers will profit from the freedom to employ these proprietary control mechanisms, without violating patent rights, when sourced from either GE Healthcare Life Sciences or Sartorius Stedim Biotech.” Reinhard Vogt, Executive Vice President of Marketing, Sales and Services, Sartorius Stedim Biotech commented: “Like GE Healthcare Life Sciences, we have primarily entered into these license agreements for the benefit of our customers. The agreement will enable both our companies to provide a greater selection of products as well as accelerate the development of new and innovative technologies for applications in the biopharmaceutical manufacturing industry.”